Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Gets Potential Oral Tysabri Follow-on In UCB Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

The company's second oral multiple sclerosis candidate employs the same mechanism as Tysabri and is set to enter Phase II early next year.

You may also be interested in...



Race To Develop Oral MS Therapy Heats Up As Novartis Releases Data Results

In Phase II studies, 77% of patients treated with Novartis' FTY720 remained relapse free after two years.

Biogen Idec Plans Multiple Sclerosis Portfolio Expansion

Aside from the marketed Avonex and Tysabri, Biogen is pursuing three other treatments through partnerships and acquisitions.

FDA Re-Approves Tysabri, Recommends Second-Line Use

Biogen Idec expects to re-launch the multiple sclerosis therapy in July.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel